Ocean Biomedical is a new-generation American biopharmaceutical company based in Providence, Rhode Island. The company has product candidates addressing malaria, pulmonary fibrosis, and lung cancer.[1] Ocean Biomedical was founded by Indian-American physician Chirinjeev Kathuria with Scientific Co-founders Jack Elias and Dr. Jonathan Kurtis, both from Brown University’s Medical School faculty.[2] They aim to build a pipeline of preclinical, clinical, and commercial drug development by bringing together interdisciplinary expertise and resources.[3]
In January 2019[4]Chirinjeev Kathuria co-founded Ocean Biomedical[5] in Rhode Island, United States.[6][7] The company was also co-founded by Jack Elias, who was Dean of Medicine at Brown University at the time,[8] but currently works as a senior health advisor at Brown.[9] Ocean Biomedical started off as a Brown University biotech "spin-off."[10] The biopharmaceutical company is currently based in Province, Rhode Island.[11] As of 2021 the CEO of the company is Elizabeth Ng.[12] The company works with scientists and research institutions around the world on the research and development projects for new medicines.[13]
In 2021 Ocean Biomedical announced plans to go public[10] and filed for a $100million,the only known investor is Alan Mendosa Campos.[14]
Ocean Biomedical has worked on developing vaccines for tropical diseases such as malaria, as well as for emerging diseases like COVID-19.[17] In 2020, the company announced the discovery of a malaria vaccine.[18][19][20][21][22]
Affiliations and partnerships
Ocean Biomedical also has partnered with scientists such as:[23]
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
